Applications for available time slots for DCP (with Latvia acting as RMS) and national authorisation procedures in 2027 will open on 15 July 2026.
As the Agency continues to receive a significant number of requests to modify medicinal products linked to already approved time-slot reservations, the Agency encourages applicants to act responsibly and reserve a submission slot only when it is certain that the marketing authorisation application will be prepared and submitted within the reserved timeframe.
The Agency also reserves the right to refuse a time-slot reservation in cases where an applicant frequently requests changes to the medicinal product covered by an already approved reservation.
More detailed information on the time slot booking tool for submission of medicinal product authorization applications is available here.
